A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...
Acute myeloid leukemia (AML) is a progressive type of cancer that affects your bone marrow and blood cells. Early detection and treatment are important to help increase the chances of survival from ...
SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...
Advancements in Interoperability: Achieving Anatomic Pathology Reports That Adhere to International Standards and Are Both Human-Readable and Readily Computable Favorable, intermediate, and adverse ...
Foghorn Therapeutics Inc. FHTX recently announced that the FDA has placed a full clinical hold on the phase I dose escalation study of pipeline candidate FHD-286 in relapsed and/or refractory acute ...
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are cancers of the blood and bone marrow. The main difference between the two is the type of white blood cell they impact. In AML, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results